GOALS AND BACKGROUND: Using natural language processing to create a nonalcoholic fatty liver disease (NAFLD) cohort in primary care, we assessed advanced fibrosis risk with the Fibrosis-4 Index (FIB-4) and NAFLD Fibrosis Score (NFS) and evaluated risk score agreement. MATERIALS AND METHODS: In this retrospective study of adults with radiographic evidence of hepatic steatosis, we calculated patient-level FIB-4 and NFS scores and categorized them by fibrosis risk. Risk category and risk score agreement was analyzed using weighted κ, Pearson correlation, and Bland-Altman analysis. A multinomial logistic regression model evaluated associations between clinical variables and discrepant FIB-4 and NFS results. RESULTS: Of the 767 patient cohorts, 71% had a FIB-4 or NFS score in the indeterminate-risk or high-risk category for fibrosis. Risk categories disagreed in 43%, and scores would have resulted in different clinical decisions in 30% of the sample. The weighted κ statistic for risk category agreement was 0.41 [95% confidence interval (CI): 0.36-0.46] and the Pearson correlation coefficient for log FIB-4 and NFS was 0.66 (95% CI: 0.62-0.70). The multinomial logistic regression analysis identified black race (odds ratio=2.64, 95% CI: 1.84-3.78) and hemoglobin A1c (odds ratio=1.37, 95% CI: 1.23-1.52) with higher odds of having an NFS risk category exceeding FIB-4. CONCLUSIONS: In a primary care NAFLD cohort, many patients had elevated FIB-4 and NFS risk scores and these risk categories were often in disagreement. The choice between FIB-4 and NFS for fibrosis risk assessment can impact clinical decision-making and may contribute to disparities of care.
GOALS AND BACKGROUND: Using natural language processing to create a nonalcoholic fatty liver disease (NAFLD) cohort in primary care, we assessed advanced fibrosis risk with the Fibrosis-4 Index (FIB-4) and NAFLD Fibrosis Score (NFS) and evaluated risk score agreement. MATERIALS AND METHODS: In this retrospective study of adults with radiographic evidence of hepatic steatosis, we calculated patient-level FIB-4 and NFS scores and categorized them by fibrosis risk. Risk category and risk score agreement was analyzed using weighted κ, Pearson correlation, and Bland-Altman analysis. A multinomial logistic regression model evaluated associations between clinical variables and discrepant FIB-4 and NFS results. RESULTS: Of the 767 patient cohorts, 71% had a FIB-4 or NFS score in the indeterminate-risk or high-risk category for fibrosis. Risk categories disagreed in 43%, and scores would have resulted in different clinical decisions in 30% of the sample. The weighted κ statistic for risk category agreement was 0.41 [95% confidence interval (CI): 0.36-0.46] and the Pearson correlation coefficient for log FIB-4 and NFS was 0.66 (95% CI: 0.62-0.70). The multinomial logistic regression analysis identified black race (odds ratio=2.64, 95% CI: 1.84-3.78) and hemoglobin A1c (odds ratio=1.37, 95% CI: 1.23-1.52) with higher odds of having an NFS risk category exceeding FIB-4. CONCLUSIONS: In a primary care NAFLD cohort, many patients had elevated FIB-4 and NFS risk scores and these risk categories were often in disagreement. The choice between FIB-4 and NFS for fibrosis risk assessment can impact clinical decision-making and may contribute to disparities of care.
Authors: N Husain; P Blais; J Kramer; M Kowalkowski; P Richardson; H B El-Serag; F Kanwal Journal: Aliment Pharmacol Ther Date: 2014-08-26 Impact factor: 8.171
Authors: Yeyi Zhu; Margo A Sidell; David Arterburn; Matthew F Daley; Jay Desai; Stephanie L Fitzpatrick; Michael A Horberg; Corinna Koebnick; Emily McCormick; Caryn Oshiro; Deborah R Young; Assiamira Ferrara Journal: Diabetes Care Date: 2019-09-19 Impact factor: 19.112
Authors: Fasiha Kanwal; Jennifer R Kramer; Hashem B El-Serag; Susan Frayne; Jack Clark; Yumei Cao; Thomas Taylor; Donna Smith; Donna White; Steven M Asch Journal: Clin Infect Dis Date: 2016-04-30 Impact factor: 9.079
Authors: Rohit Loomba; Robert Wong; Jeremy Fraysse; Sanatan Shreay; Suying Li; Stephen Harrison; Stuart C Gordon Journal: Aliment Pharmacol Ther Date: 2020-05-05 Impact factor: 8.171
Authors: Erin R Cleveland; Hongyan Ning; Miriam B Vos; Cora E Lewis; Mary E Rinella; John Jeffrey Carr; Donald M Lloyd-Jones; Lisa B VanWagner Journal: J Gen Intern Med Date: 2019-10-08 Impact factor: 5.128